Can BridgeBio’s Attruby narrow Pfizer’s Vyndamax lead in the ATTR-CM market?
Pfizer owns the ATTR-CM legacy. BridgeBio now has data that could test whether clinical differentiation can move prescribing habits.
Can Alnylam’s AMVUTTRA become a first-line treatment force in ATTR-CM?
ATTR-CM treatment is shifting earlier. Alnylam must now prove AMVUTTRA can win clinician trust beyond trial subgroups.